(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

thereby delivering targeted radiation to cancer cells in the body with minimal damage to surrounding healthy cells: Up to 100 patients with treatment naive, biopsy-proven clear cell RCC with adequate ...

Cancer cells work together to source nutrients from their environment—a cooperative process that was previously overlooked by ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...

papillary RCC and chromophobe RCC. Metabolic dysregulation in the development of clear cell renal cell carcinoma (ccRCC) remains to be understood. Here the authors identify that a carnitine ...

The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their ...

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma. Among patients with renal cell ...

Highlighted here are abstracts that address ongoing struggles to address clinical trial diversity in renal cell carcinoma (RCC ... CheckMate 9ER, CLEAR, KEYNOTE 564, LITESPARK 005, and TIVO ...